Co-Feedback Action of Growth Hormone, PP and PYY on Ghrelin in Bulimia
Launched by CHARLES UNIVERSITY, CZECH REPUBLIC · Nov 7, 2017
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Acipimox and exercise each increase growth hormone release, but they do so by different mechanisms.
Acipimox is an anti-lipolytic drug and increases growth hormone release by decreasing free fatty acids levels and that Acipimox may exert to a negative feedback of growth hormone on ghrelin.
Physical exercise is a potent physiological stimulus for growth hormone release. As ghrelin has a stimulatory effect on growth hormone secretion, growth hormone may inhibit circulating ghrelin levels via a feedback loop. Growth hormone stimulates lipolysis and resultant free fatty acids may suppress ghr...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with a diagnosis of bulimia nervosa
- • Body mass index (BMI) between 18 and 23 kg/m2
- Exclusion Criteria:
- • History of heart disease
- • History of bleeding disorders
- • Subjects with diabetes type 1 or 2, hypo- or hyperthyroidism
- • Subjects with hepatogastroenteric disease
- • Pregnant, trying to become pregnant or breast feeding
- • Patients with other psychiatric diseases
About Charles University, Czech Republic
Charles University, located in the Czech Republic, is a prestigious institution renowned for its commitment to advancing medical research and education. As a clinical trial sponsor, the university leverages its extensive academic expertise and state-of-the-art facilities to conduct innovative research that aims to improve patient outcomes and contribute to the global medical community. With a focus on ethical standards and rigorous scientific methodologies, Charles University collaborates with various stakeholders to explore new therapies and enhance healthcare practices, fostering a culture of excellence in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Kvido Smitka, M.D., Ph.D.
Principal Investigator
Charles University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials